Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms

As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers.  This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

Target Audience

This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Identify clinical challenges in managing patients with with plasma cell neoplasms. 
  • Develop an evidence-based approach for the management of these patients. 
Additional information

This activity is supported by educational grants from: 

  • AstraZeneca
  • Daiichi Sankyo 
  • Gilead Sciences, Inc. and Kite, A Gilead Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seagen Inc. (formerly Seattle Genetics, Inc.)
  • Takeda

This activity is supported by independent medical education grants from:

  • ADC Therapeutics
  • Bristol Myers Squibb
  • MorphoSys
  • Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
Course expires: 


Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center


Jorge J. Castillo, MD
Dana-Farber Cancer Institute

Carol Ann Huff, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Michaela Liedtke, MD
Stanford Cancer Institute


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Jorge J. Castillo, MD
AbbVie, Inc.: Grant/Research Support; Honoraria
BeiGene: Grant/Research Support; Honoraria
Janssen Pharmaceutica Products, LP: Honoraria
Pharmacyclics: Grant/Research Support; Honoraria
Roche Laboratories, Inc.: Honoraria 
TG Therapeutics, Inc.: Grant/Research Support 

Carol Ann Huff, MD
AstraZeneca Pharmaceuticals LP: Honoraria
GlaxoSmithKline: Honoraria
Oncopeptides: Honoraria
sanofi-aventis U.S.: Honoraria 

Michaela Liedtke, MD
Allogene Therapeutics: Grant/Research Support 
Alnylam Pharmaceuticals, Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Caelum Biosciences, Inc.: Grant/Research Support 
Celgene Corporation: Grant/Research Support
GlaxoSmithKline: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Scientific Advisor
Kite Pharma: Scientific Advisor
Kura Oncology, Inc.: Scientific Advisor
Natera, Inc.: Scientific Advisor
Oncopeptides: Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor
Seattle Genetics, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support; Scientific Advisor
BMS/Celgene/Juno: Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.25 contact hours.

NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.0125 CEUs) of continuing education credit. UAN: JA4008196-0000-21-121-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing